India's Jubilant Pharmova falls on likely US FDA violations
** Shares of Jubilant Pharmova JUBA.NS slide as much as
6%, before finishing the day 2.5% lower
** Pharma company says US FDA closed inspection of Montreal
manufacturing facility with 15 observations, which indicates
likely regulatory violations
** US FDA has issued three observations on a Washington
facility last week
** Stock has gained 34.5% YTD
(Reporting by Nishit Navin)
((nishit.navin@thomsonreuters.com;))
Recent news on Jubilant Pharmova
See all newsBrief: Jubilant Pharmova Sept-Quarter Consol Net Profit 312 Million Rupees
Brief: Jubilant Pharmova Says Jubilant Therapeutics Announces Oral Presentation Of Preliminary Phase 1 Clinical Data For JBI-802
India New Issue-Jubilant Pharmova to issue 3-year bonds, bankers say
India's Jubilant Pharmova eyes $150 mln through rupee debt sale, bankers say
Brief: Jubilant Pharmova To Consider Raising Of Funds Through Issuance Of Non- Convertible Debentures